IVVD Doubled on Clinical Trial Results

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Earnings in 48 days. Avg 30D Vol at 24.67M Current Vol at 74.70M

Can this break and retest $2.35? If it does analyst have targets as high as $10. GL!